Login to Your Account

Financings Roundup

Amicus Doubles Cash in $57M Offering; Amigal Data in 3Q12

By Jennifer Boggs
Managing Editor

Monday, March 5, 2012
Awaiting much-anticipated data from its pivotal Fabry disease program later this year, Amicus Therapeutics Inc. is doubling its cash balance via a $57 million public offering.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription